Oct 5, 2026 · 43 min
Dollar strength reshapes bets across tech, banks and global markets
Strong Dollar Keeps Climbing… And The Outlook For The Pharma Trade 10/5/26
Rising yields and a stronger dollar are forcing investors to reassess equity leadership, international exposure and opportunities in energy and healthcare.
- 1Higher yields have not stopped technology’s advance, but valuations, earnings growth and market concentration remain central risks.
- 2Energy stocks are gaining despite weaker oil prices as investors weigh improved earnings power, geopolitics and an under-owned sector.
- 3Pharmaceutical M&A favors late-stage biotech assets while Novo Nordisk faces pressure from Lilly’s strength and shifting therapeutic opportunities.
Don't miss
The panel weighs whether a prediction-market contract on U.S. confirmation of extraterrestrial life could ever define credible evidence.
The brief
The dollar reaches more than one-year highs as strong services data, Federal Reserve expectations and political volatility in France fuel a flight to quality.
Technology continues to outperform despite higher Treasury yields, but the panel questions mega-cap valuations, earnings growth and the risks of concentrated leadership.
JP Coviello outlines a year-end strategy favoring technology and banks, with commodities, gold and potentially Treasuries adding diversification as multiples compress.
Energy equities rise while crude falls, prompting debate over oil services, refiners, geopolitical risk and whether improved earnings power can attract investors.
The healthcare discussion turns to pharmaceutical M&A, late-stage biotech assets and novel therapies, while Novo Nordisk confronts Lilly’s strength.
Brazil’s election-driven rally and unusual prediction-market contracts broaden the discussion, from currency and banks to recession odds and extraterrestrial disclosure.
What was said on this episode
39 statements · 27 positive · 11 negative · 1 neutral
Historically, a stronger dollar has pressured equity markets.
“a higher dollar historically has created a bit of a headwind for equity markets”
Listen at 3:02
Long-duration assets are currently unattractive.
“Duration is not your friend right now.”
Listen at 5:01
Technology should remain part of a safety-oriented equity allocation.
“it should”
Listen at 6:34
Investors may soon shift toward gold as market deterioration becomes apparent.
“maybe we should be in gold after all. And that's coming to a theater near you really soon.”
Listen at 7:40
Technology is currently serving as the market’s flight-to-quality destination.
“the flight to quality is absolutely to tech”
Listen at 8:58
NVIDIA appears attractively valued at 17 times forward earnings.
“at 17 times forward, I mean, it looks like a no-brainer”
Listen at 9:19
Any deterioration in NVIDIA demand would significantly affect its valuation and earnings outlook.
“if there is any deterioration in that demand, you're going to feel it pretty profoundly ripple through”
Listen at 10:14
Banks should trade at higher valuations than they currently do.
“I think banks should be trading better than they do.”
Listen at 11:30
Index valuations have compressed to about 19 times, attractive versus the five-year history.
“That multiple compression has brought us down to about 19 times at an index level, which over a five-year look back looks pretty good to us.”
Listen at 13:31
Upstream natural resources and commodities are important portfolio diversifiers.
“upstream natural resources, commodities for us are a big piece of our diversification move”
Listen at 14:00
CitiWealth has added gold to replace duration exposure in portfolios.
“We have added to gold over the past year and a half to replace some of our duration in portfolios.”
Listen at 14:07
The current market is not close to the cycle phase favoring an overweight in duration.
“we're just not even close to that”
Listen at 15:41
Treasury yields are likely to rise further.
“yields likely do move higher from here”
Listen at 16:19
Technology earnings are expected to grow 27 percent this quarter.
“Expecting 27 percent growth this quarter”
Listen at 16:31
Treasuries offer potentially attractive total returns over the next six months.
“there is a total return component of buying some treasuries right now that I think will be interesting for the next six months”
Listen at 17:17
Economic softness would improve Treasury pricing in the near term.
“if there is softness, I think you will see a lot of improvement in the pricing of these yields for, you know, probably the near term at least”
Listen at 17:36
The market’s rise is being driven by unfavorable reasons.
“I continue to think wrong reasons.”
Listen at 18:06
Energy equities remain under-owned and worth holding long.
“I think it's under-owned. Still, maybe not as much, but still under-owned. I'm still staying long.”
Listen at 19:51
Valero, Marathon, and PSX possess unusually strong earnings power.
“they continue to trade like they have earnings power like they've never had, which, by the way, they do.”
Listen at 20:12
Energy equities offer upside that the market has not fully priced.
“there's a chance to be buying upside in energy names that the market is not pricing in”
Listen at 21:11
Chipotle is unattractive at 27 times forward earnings amid core-business pressure.
“I don't think at 27 times forward in the environment we're in, especially when there's a lot more pressure on their core business, that I want to be going out and chasing this thing.”
Listen at 23:22
Chipotle remains expensive despite its recent decline.
“it's not a cheap stock, unfortunately”
Listen at 24:06
Investors should avoid Chipotle temporarily.
“I think you've got to stay away for a while.”
Listen at 24:18
Restaurant stock multiples remain excessively high despite rising rates.
“The multiples should be less high. And yet they're still stratospheric.”
Listen at 24:31
McDonald’s offers greater business stability than Chipotle.
“probably McDonald's. I think there's more stability under this business.”
Listen at 25:48
Pharmaceutical companies completed approximately $135 billion in M&A during 2026.
“Pharma, you know, racking up around $135 billion in deals”
Listen at 28:02
Pharma’s bolt-on M&A supports biotech valuations in the $1–$10 billion range.
“That's good for biotech because biotech is usually going to be priced in that $1 to $10 billion category”
Listen at 28:12
AbbVie’s acquired Cerevel product is currently used for Parkinson’s disease.
“That product is being used now in Parkinson's.”
Listen at 29:37
Longevity investors generally pursue broader wellness and health opportunities.
“longevity investors tend to be investors that are interested in wellness, in health, that are much broader based”
Listen at 30:59
Novo Nordisk retains long-term value despite current investor impatience.
“Looking over the longer term, I still believe that Novo has value”
Listen at 32:33
Chinese biotech licensing activity is likely to grow aggressively over the next few years.
“watch for them to grow really aggressively in the next few years”
Listen at 33:19
Long-term holders of Novo Nordisk are likely to be rewarded.
“hold for a long time and likely you'll be rewarded”
Listen at 33:28
China’s share of pharmaceutical drug development rose from 8% to about 32%.
“China represented about 8% in 2015 of pharma drug development. It's gone to about 32% today.”
Listen at 34:02
The U.S. share of pharmaceutical drug development declined from 48% to about 37%.
“U.S. was at about 48% of share. It's down to about 37%.”
Listen at 34:11
A more market-friendly Brazilian government would strengthen Brazil’s currency and credit profile.
“what it does translate into is a stronger currency, a stronger at least credit profile of the country”
Listen at 36:50
Brazil’s equity ETF trades cheaply relative to many peers.
“At a valuation that's cheap to a lot of its peers”
Listen at 37:30
HealthEquity offers rate exposure, while HSAs are likely to remain relevant.
“I like health equity. It gives you the exposure to rates, and, you know, HSAs are probably here for a while.”
Listen at 42:04
EEM is the recommended final trade.
“EEM.”
Listen at 42:21
Citigroup is favored ahead of next week’s earnings.
“Next week, I like Citigroup going in.”
Listen at 42:31
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.